AMRX Q4 2020 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q4 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$510M+28.4% YoY

Gross Profit

$167M32.8% margin

Operating Income

$20M4.0% margin

Net Income

-$3M-0.6% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

-1.8%

Cash Flow

Operating Cash Flow

$106M

Free Cash Flow

$75M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$4.0B

Total Liabilities

$3.6B

Stockholders' Equity

$303M

Cash & Equivalents

$341M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$510M	$397M	+28.4%
Gross Profit	$167M	$110M	+51.6%
Operating Income	$20M	-$23M	+187.2%
Net Income	-$3M	-$32M	+90.5%

Revenue Segments

Generics Segment

$342M80%

Amneal Specialty Pharma Segment

$85M20%